Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

Similar articles for PubMed (Select 18506160)

1.

Is mizoribine a new therapeutic agent for Sjögren's syndrome?

Moutsopoulos HM, Fragoulis GE.

Nat Clin Pract Rheumatol. 2008 Jul;4(7):350-1. doi: 10.1038/ncprheum0823. Epub 2008 May 27.

PMID:
18506160
2.

Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial.

Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, Ito S, Minota S, Nara H, Kondo H, Okada J, Mimori T, Yoshifuji H, Sano H, Hashimoto N, Sugai S, Tanaka Y.

Mod Rheumatol. 2007;17(6):464-9. Epub 2007 Dec 20.

PMID:
18084697
3.

A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.

Khurshudian AV.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jan;95(1):38-44.

PMID:
12539025
4.

Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial.

Sugai S, Takahashi H, Ohta S, Nishinarita M, Takei M, Sawada S, Yamaji K, Oka H, Umehara H, Koni I, Sugiyama E, Nishiyama S, Kawakami A.

Mod Rheumatol. 2009;19(2):114-24. doi: 10.1007/s10165-008-0141-1. Epub 2008 Dec 17.

PMID:
19089532
5.

Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial.

Nakayamada S, Saito K, Nakatsuka K, Nakano K, Tokunaga M, Sawamukai N, Tsujimura S, Nawata M, Tanaka Y.

Mod Rheumatol. 2003 Dec;13(4):339-45. doi: 10.3109/s10165-003-0247-4.

PMID:
24387256
6.
7.

Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy.

Nakayamada S, Fujimoto T, Nonomura A, Saito K, Nakamura S, Tanaka Y.

Rheumatology (Oxford). 2009 Oct;48(10):1279-82. doi: 10.1093/rheumatology/kep228. Epub 2009 Aug 11.

8.

Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study.

Papas AS, Sherrer YS, Charney M, Golden HE, Medsger TA Jr, Walsh BT, Trivedi M, Goldlust B, Gallagher SC.

J Clin Rheumatol. 2004 Aug;10(4):169-77.

PMID:
17043506
9.

Use of orally administered anhydrous crystalline maltose for relief of dry mouth.

Fox PC, Cummins MJ, Cummins JM.

J Altern Complement Med. 2001 Feb;7(1):33-43.

PMID:
11246934
10.

Cevimeline.

Weber J, Keating GM.

Drugs. 2008;68(12):1691-8.

PMID:
18681491
11.

Opening the flood gates: interferon-alpha treatment for Sjögren's syndrome.

Shiozawa S, Cummins JM, Fox PC.

BioDrugs. 2000 May;13(5):305-11.

PMID:
18034537
12.

[Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].

György B, Robert K, László C, Andrea J; Ketilept Vizsgáló Munkacsoport.

Neuropsychopharmacol Hung. 2008 Dec;10(5):293-303. Hungarian.

13.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
14.

[Salivary gland scintigraphy in the evaluation of patients with sicca complaints].

Vinagre F, Santos A, Santos M, Prata A, Oliveira A, Silva JC.

Acta Reumatol Port. 2008 Oct-Dec;33(4):422-8. Portuguese.

15.

[Applicability of syalometry and other instruments to evaluate xerostomia and xerophtalmia in a Sjögren's Syndrome outpatient clinic].

Barcelos F, Patto JV, Parente M, Medeiros D, Sousa M, Figueiredo R, Miguel C, Teixeira A.

Acta Reumatol Port. 2009 Apr-Jun;34(2A):212-8. Portuguese.

16.

Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome.

Mavragani CP, Skopouli FN, Moutsopoulos HM.

J Rheumatol. 2009 Aug;36(8):1626-30. doi: 10.3899/jrheum.081326. Epub 2009 Jul 15.

PMID:
19605678
17.

Oral involvement in primary Sjögren syndrome.

Fox PC, Bowman SJ, Segal B, Vivino FB, Murukutla N, Choueiri K, Ogale S, McLean L.

J Am Dent Assoc. 2008 Dec;139(12):1592-601.

PMID:
19047665
18.

The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome.

Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M, Canavan A, Hamburger J, Richards A, Regan M, Gadsby K, Rigby S, Jones A, Mathew R, Mulherin D, Stevenson A, Nightingale P, Rauz S, Bowman SJ.

Rheumatology (Oxford). 2008 Aug;47(8):1193-8. doi: 10.1093/rheumatology/ken164. Epub 2008 Jun 4.

20.

Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis.

Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, Guias B, Pennec Y, Pers JO, Daridon C, Jamin C, Renaudineau Y, Roué IQ, Cochener B, Bressollette L, Youinou P, Saraux A.

Biologics. 2007 Sep;1(3):311-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk